Chugai Pharmaceutical Co., Ltd. (CHGCY)

Market Cap	55.25B
Revenue (ttm)	7.18B
Net Income (ttm)	2.10B
Shares Out	3.29B
EPS (ttm)	1.28
PE Ratio	26.00
Forward PE	24.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,479
Open	17.21
Previous Close	16.64
Day's Range	16.47 - 17.21
52-Week Range	12.28 - 22.61
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CHGCY

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu,...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,604
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCY

Financial Performance

In 2023, CHGCY's revenue was 1.11 trillion, a decrease of -11.79% compared to the previous year's 1.26 trillion. Earnings were 325.47 billion, a decrease of -13.08%.

Financial numbers in JPY